ମାରିବାଭିର

ମାରିବାଭିର
Clinical data
Trade names	Livtencity
Synonyms	1263W94
AHFS/Drugs.com	monograph
data	US DailyMed: Maribavir;
Routes of; administration	By mouth
Legal status
Legal status	CA: ℞-only ; US: ℞-only ;
Identifiers
	IUPAC name (2S,3S,4R,5S)-2-[5,6-Dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol;
Chemical and physical data
Formula	C15H19Cl2N3O4
Molar mass	୩୭୬.୨୩ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)Nc1nc2cc(c(cc2n1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl;
	InChI InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1 ; Key:KJFBVJALEQWJBS-XUXIUFHCSA-N ;
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Maribavir

ମାରିବାଭିର (ଇଂରାଜୀ ଭାଷାରେ Maribavir), ଲିଭଟେନ୍ସି ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଭୂତାଣୁରୋଧୀ ଔଷଧ ଯାହା ଟ୍ରାନ୍ସପ୍ଲାଣ୍ଟ ପରବର୍ତ୍ତୀ ସାଇଟୋମେଗାଲୋଭାଇରସ (CMV) ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ସେହି କ୍ଷେତ୍ରରେ ବ୍ୟବହୃତ ହୁଏ ଯେଉଁଠାରେ ଗାନିକ୍ଲୋଭିର, ଭାଲଗାନିକ୍ଲୋଭିର, ସିଡୋଫୋଭିର, ଏବଂ ଫୋସ୍କାରନେଟ ଇତ୍ୟାଦି ପ୍ରଭାବଶାଳୀ ହୁଏନି ।^[୨] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସ୍ୱାଦ ବ୍ୟାଘାତ, ଅଇ, ତରଳ ଝାଡ଼ା, ବାନ୍ତି ଏବଂ ଥକ୍କାଣ ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ବିଷୟ ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୨] ଏହା ଏକ ସାଇଟୋମେଗାଲୋଭାଇରସ ପିୟୁଏଲ୯୭ କାଇନେଜ ଇନହିବିଟର (cytomegalovirus pUL97 kinase inhibitor) ହୋଇଥିବାରୁ ଜୀବାଣୁ ନକଲକୁ ଅବରୋଧ କରେ ।^[୨]

୨୦୨୧ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ମାରିବାଭିର ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ୨୦୨୨ ସୁଦ୍ଧା ୟୁରୋପରେ ଅନୁମୋଦନ ପାଇଁ ସୁପାରିଶ କରାଯାଇଛି ।^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୨ ସୁଦ୍ଧା ୪ ସପ୍ତାହ ବ୍ୟବ‌ହାରର ମୂଲ୍ୟ ପ୍ରାୟ ୨୫୦୦୦ ଡଲାର ଥିଲା ।^[୫]

ଆଧାର

↑ https://pdf.hres.ca/dpd_pm/00067349.PDF Archived 1 October 2022 at the Wayback Machine. ଛାଞ୍ଚ:Bare URL PDF
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ "Livtencity- maribavir tablet, coated". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.
↑ "FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs". U.S. Food and Drug Administration (FDA) (Press release). 23 November 2021. Archived from the original on 24 November 2021. Retrieved 23 November 2021. This article incorporates text from this source, which is in the public domain.
↑ "Maribavir". SPS - Specialist Pharmacy Service. 18 January 2017. Archived from the original on 5 March 2022. Retrieved 24 October 2022.
↑ "Maribavir". Goodrx. Archived from the original on 24 October 2022. Retrieved 24 October 2022.

[1] ttps://pdf.hres.ca/dpd_pm/00067349.PDF Archived 1 October 2022 at the Wayback Machine. ଛାଞ୍ଚ:Bare URL PDF

[PI2022-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ "Livtencity- maribavir tablet, coated". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.

[FDA2022PR-3] "FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs". U.S. Food and Drug Administration (FDA) (Press release). 23 November 2021. Archived from the original on 24 November 2021. Retrieved 23 November 2021. This article incorporates text from this source, which is in the public domain.

[SPS2022-4] "Maribavir". SPS - Specialist Pharmacy Service. 18 January 2017. Archived from the original on 5 March 2022. Retrieved 24 October 2022.

[5] "Maribavir". Goodrx. Archived from the original on 24 October 2022. Retrieved 24 October 2022.

[୧]

[୨]

[୩]

[୪]

[୫]